Home » Newsletters » BioWorld Science

BioWorld Science

May 31, 2001

View Archived Issues

Novel inhibitors of p53 available from NIH for several therapeutic indications

Biologically active macrolides available for licensing from NIH

New dose of Teveten now available in Canada

Shire reports positive phase III results for SLI-381 in ADHD

Provigil has beneficial effects in depression; marketing and distribution agreement announced

Excellent efficacy reported for new triazole KP-103 in superficial fungal infections

Antiangiogenic effects of KR-31372 demonstrated in rats

Binding and functional activity of first selective OX1 receptor antagonist characterized

Biosearch Italia may reacquire rights to ramoplanin; IntraBiotics focuses on iseganan

Antiatherosclerotic effects of ACAT inhibitor avasimibe confirmed in ApoE*3-Leiden mice

M&E Biotech now Pharmexa

Genaera's squalamine receives orphan drug status in U.S.

ATS 2001: preclinical and clinical findings support development of roflumilast in asthma, COPD

Synergies between CT-3 and opioids to be studied

Icos and Texas Biotechnology initiate phase II/III trial of sitaxsentan in pulmonary hypertension

Expanded potential of CI-1042, a replication-selective adenovirus targeting p53, emerges at ASCO

Demegen anticipates IND submission for infected burn/wound treatment

Purine derivatives identified as adenosine A2A agonists at Pfizer

Lilly presents new compounds for reversing MDR

Caspase 3 inhibitors from Merck Frosst active in rat model of myocardial ischemia

Highly selective factor Xa inhibitors emerge from R&D at Corvas

Protherics designs new tryptase inhibitors particularly useful in asthma Rx

Monoamine reuptake inhibitors and uses thereof disclosed by Pfizer team

Recent patent covers new MMP inhibitors developed at Sankyo